The Lugano 2014 criteria are the standard for response assessment in lymphoma. We compared the prognostic performance of Lugano 2014 and the more recently developed response evaluation criteria in lymphoma (RECIL 2017), which relies primarily on computed tomography and uses unidimensional measurements, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) from the phase III GOYA and GALLIUM trials, respectively. Concordance between responses according to the Lugano 2014 and RECIL 2017 criteria was analyzed. Landmark analyses of progression-free survival (PFS) and overall survival (OS) by end of treatment (EOT) and end of induction (EOI) response status according to RECIL 2017 and Lugano 2014 criteria, and prognostic value of response at EOT/EOI were also compared. Overall, 1333 patients were included from GOYA and 502 from GALLIUM. Complete response (CR) status according to RECIL 2017 criteria showed high concordance with complete metabolic response (CMR) status by Lugano 2014 criteria in both GOYA (92.5%) and GALLIUM (92.4%). EOT and EOI CR/CMR status by both criteria was highly prognostic for PFS in GOYA (RECIL 2017 [CR]: hazard ratio [HR], 0.35 [95% confidence interval [CI] 0.26-0.46]; Lugano 2014 [CMR]: HR, 0.35 [95% CI 0.26-0.48]; both p < .0001) and GALLIUM (RECIL 2017 [CR]: HR, 0.35 [95% CI 0.23-0.53]; Lugano 2014 [CMR]: HR, 0.21 [95% CI 0.14-0.31]; both p < .0001). In conclusion, response categorization by RECIL 2017 is similar to that by Lugano 2014 criteria, with high concordance observed. Both were prognostic for PFS and OS.

1st Faculty of Medicine Charles University General Hospital Prague Czech Republic

AstraZeneca New York New York USA

BC Cancer Center for Lymphoid Cancer and the University of British Columbia Vancouver British Columbia Canada

Cancer Research UK Centre NIHR Experimental Cancer Medicine Centre University of Southampton Southampton UK

Concord Repatriation General Hospital University of Sydney Concord New South Wales Australia

Department of Radiology and Medical Imaging University of Virginia Charlottesville Virginia USA

F Hoffmann La Roche Ltd Basel Switzerland

HELIOS Klinikum Erfurt Erfurt Germany

Hematology Department of Translational and Precision Medicine Sapienza University Rome Italy

Medical Oncology Candiolo Cancer Institute FPO IRCCS Candiolo Italy

Memorial Sloan Kettering Cancer Center New York City New York USA

University Hospital Munich Munich Germany

Zobrazit více v PubMed

Cancer.net Editorial Board . Lymphoma—non‐Hodgkin: subtypes. Cancer.net. 2021. Accessed August 31, 2023. https://www.cancer.net/cancer‐types/lymphoma‐non‐hodgkin/subtypes

Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez‐Guillermo A, et al. Diffuse large B‐cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2015;26(Suppl 5):v116–v125. PubMed

Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, et al. A randomized, open‐label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B‐cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71. PubMed PMC

Wang L. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175. PubMed PMC

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B‐cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537. PubMed

Dreyling M, Ghielmini M, Rule S, Jerkeman M, Le Gouill S, Rule S, et al.. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32(3):298–308. PubMed

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first‐line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344. PubMed

Cheah CY, Seymour JF. When to treat patients with relapsed follicular lymphoma. Expert Rev Hematol. 2017;10(3):187–191. PubMed

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244. PubMed

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. PubMed

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. PubMed PMC

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. PubMed

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436–1447. PubMed PMC

Assouline S, Meyer RM, Infante‐Rivard C, Connors JM, Belch A, Crump M, et al. Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leuk Lymphoma. 2007;48(3):513–520. PubMed

Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45(2):261–267. PubMed

Kostakoglu L. End‐of‐treatment PET/CT predicts PFS and overall survival in DLBCL after first‐line treatment: results from GOYA. Blood Adv. 2021;5(5):1283–1290. PubMed PMC

Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, et al. Prognostic value of end‐of‐induction PET response after first‐line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530–1542. PubMed

Berzaczy D, Haug A, Staber PB, Raderer M, Kiesewetter B, Jaeger U, et al. RECIL versus Lugano for treatment response assessment in FDG‐avid non‐Hodgkin lymphomas: a head‐to‐head comparison in 54 patients. Cancers (Basel). 2019;12(1):9. PubMed PMC

Kaddu‐Mulindwa D, Gödel P, Kutsch N, Heger J‐M, Scheid C, Borchmann P, et al. Salvage agent high‐dose melphalan with autologous stem cell transplantation as bridge to consolidation therapy for chemoresistant aggressive B‐cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(7):e498–e506. PubMed

Haverkos B, Zain J, Kamdar M, Neuwelt A, Bair SM, Jasem J, et al. A pilot study using nivolumab in combination with standard of care chemotherapy in newly diagnosed peripheral T‐cell lymphomas. Blood. 2021;138(Suppl 1):2444.

Long NM, Smith CS. Causes and imaging features of false positives and false negatives on F‐PET/CT in oncologic imaging. Insights Imaging. 2011;2(6):679–698. PubMed PMC

Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496. PubMed